Expand APRE Menu
APRE MENU

APRE Latest Press Releases

-- July 30, 2026 --

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 Globe Newswire 8:00 AM

-- June 22, 2026 --

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology Globe Newswire 8:30 AM

-- June 1, 2026 --

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors Globe Newswire 8:00 AM

-- May 13, 2026 --

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Globe Newswire 6:30 AM

-- April 28, 2026 --

CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors Business Wire 7:00 AM

-- April 21, 2026 --

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting Globe Newswire 10:15 AM

-- April 6, 2026 --

Frazier Life Sciences Appoints Christian Schade as Senior Advisor Business Wire 8:00 AM

-- April 1, 2026 --

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement Globe Newswire 8:30 AM

-- March 30, 2026 --

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement Globe Newswire 8:01 AM
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial Globe Newswire 8:00 AM

-- March 16, 2026 --

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes